187 related articles for article (PubMed ID: 35867969)
1. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients.
Wong S; Ehrhart EJ; Stewart S; Zismann V; Cawley J; Halperin R; Briones N; Richter K; Sivaprakasam K; Perdigones N; Contente-Cuomo T; Facista S; Trent JM; Murtaza M; Khanna C; Hendricks WPD
PLoS One; 2022; 17(7):e0264986. PubMed ID: 35867969
[TBL] [Abstract][Full Text] [Related]
2. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma.
Estabrooks T; Gurinovich A; Pietruska J; Lewis B; Harvey G; Post G; Lambert L; Miller A; Rodrigues L; White ME; Lopes C; London CA; Megquier K
Vet Comp Oncol; 2023 Dec; 21(4):623-633. PubMed ID: 37734854
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma.
Wong K; Ludwig L; Krijgsman O; Adams DJ; Wood GA; van der Weyden L
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 34296746
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma.
Wang G; Wu M; Durham AC; Radaelli E; Mason NJ; Xu X; Roth DB
PLoS One; 2020; 15(3):e0229728. PubMed ID: 32210430
[TBL] [Abstract][Full Text] [Related]
5. Actionable mutations in canine hemangiosarcoma.
Wang G; Wu M; Maloneyhuss MA; Wojcik J; Durham AC; Mason NJ; Roth DB
PLoS One; 2017; 12(11):e0188667. PubMed ID: 29190660
[TBL] [Abstract][Full Text] [Related]
6. Chromatin run-on sequencing analysis finds that ECM remodeling plays an important role in canine hemangiosarcoma pathogenesis.
Mukai C; Choi E; Sams KL; Klampen EZ; Anguish L; Marks BA; Rice EJ; Wang Z; Choate LA; Chou SP; Kato Y; Miller AD; Danko CG; Coonrod SA
BMC Vet Res; 2020 Jun; 16(1):206. PubMed ID: 32571313
[TBL] [Abstract][Full Text] [Related]
7. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
[TBL] [Abstract][Full Text] [Related]
8. A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs.
Grimes JA; Prasad N; Levy S; Cattley R; Lindley S; Boothe HW; Henderson RA; Smith BF
BMC Vet Res; 2016 Dec; 12(1):272. PubMed ID: 27912752
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions.
Favaro PF; Stewart SD; McDonald BR; Cawley J; Contente-Cuomo T; Wong S; Hendricks WPD; Trent JM; Khanna C; Murtaza M
Sci Rep; 2022 Apr; 12(1):6337. PubMed ID: 35428782
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*.
Thamm DH; Kamstock DA; Sharp CR; Johnson SI; Mazzaferro E; Herold LV; Barnes SM; Winkler K; Selting KA
Vet Comp Oncol; 2012 Dec; 10(4):292-302. PubMed ID: 22236280
[TBL] [Abstract][Full Text] [Related]
11. Refining the "double two-thirds" rule: Genotype-based breed grouping and clinical presentation help predict the diagnosis of canine splenic mass lesions in 288 dogs.
Davies O; Taylor AJ
Vet Comp Oncol; 2020 Dec; 18(4):548-558. PubMed ID: 32043696
[TBL] [Abstract][Full Text] [Related]
12. Identification of serum microRNAs with differential expression between dogs with splenic masses and healthy dogs with histologically normal spleens.
Grimes JA; Robinson KR; Bullington AM; Schmiedt JM
Am J Vet Res; 2021 Aug; 82(8):659-666. PubMed ID: 34296940
[TBL] [Abstract][Full Text] [Related]
13. Prospective observational study of dogs with splenic mass rupture suggests potentially lower risk of malignancy and more favourable perioperative outcomes.
Stewart SD; Ehrhart EJ; Davies R; Khanna C
Vet Comp Oncol; 2020 Dec; 18(4):811-817. PubMed ID: 32458544
[TBL] [Abstract][Full Text] [Related]
14. Can CT texture analysis parameters be used as imaging biomarkers for prediction of malignancy in canine splenic tumors?
Choi BK; Park S; Lee G; Chang D; Jeon S; Choi J
Vet Radiol Ultrasound; 2023 Mar; 64(2):224-232. PubMed ID: 36285434
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma.
Adachi M; Hoshino Y; Izumi Y; Takagi S
J Vet Med Sci; 2016 May; 78(4):649-56. PubMed ID: 26685984
[TBL] [Abstract][Full Text] [Related]
16. Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma.
Musser ML; Coto GM; Lingnan Y; Mochel JP; Johannes CM
PLoS One; 2022; 17(12):e0279594. PubMed ID: 36548371
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005).
Hammond TN; Pesillo-Crosby SA
J Am Vet Med Assoc; 2008 Feb; 232(4):553-8. PubMed ID: 18279091
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma.
Thomas R; Borst L; Rotroff D; Motsinger-Reif A; Lindblad-Toh K; Modiano JF; Breen M
Chromosome Res; 2014 Sep; 22(3):305-19. PubMed ID: 24599718
[TBL] [Abstract][Full Text] [Related]
19. Hyperferritinemia in dogs with splenic hemangiosarcoma.
Chikazawa S; Hori Y; Hoshi F; Kanai K; Ito N; Higuchi S
J Vet Med Sci; 2013 Nov; 75(11):1515-8. PubMed ID: 23803459
[TBL] [Abstract][Full Text] [Related]
20. Splenic masses in dogs. Part 1: Epidemiologic, clinical characteristics as well as histopathologic diagnosis in 249 cases (2000-2011).
Eberle N; von Babo V; Nolte I; Baumgärtner W; Betz D
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(4):250-60. PubMed ID: 22911256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
